October 25, 2023 — Elixir Medical, developer of novel cardiovascular technologies, announced positive six-month clinical data from the DESyne BDS Plus Randomized Controlled Trial (RCT) during the Transcatheter Cardiovascular Therapeutics (TCT) conference, TCT 2023, in San Francisco, CA.
